Close Menu

Sciex

The Roslin, UK-based firm, which sells instruments and software for printing arrays, has entered into a non-exclusive co-marketing arrangement with MDS. American Medical Link, meantime, has agreed to support and service Arrayjet instruments in the US and Canada.

Despite the gyrations on Wall Street, the stocks of the largest mass spectrometer manufacturers rose an average of almost 48 percent for the first half of 2009, according to ProteoMonitor's sister publication GenomeWeb Daily News.

MDS announced its plans to sell the business to INC for $50 million in early June as part of a broader strategy to focus the MDS Pharma Services business on services for early-stage discovery through Phase IIa, where it said it holds a "top-three" position in the market.

For the three months ended April 30, the company, which has a joint-venture agreement with Life Technologies' Applied Biosystems on mass specs, said its Analytical Technologies revenues fell to $87 million, down from $118 million in Q2 2008.

MDS also swung to a loss in the quarter. Its mass spec sales sagged amid "soft end-user demand," the firm said.

MDS Pharma Services' expansion in Taiwan is in line with the unit's decision to focus on early-stage discovery and development services.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Proteomics

The AB Sciex TOF/TOF 5800, which the companies said enables researchers to identify 30 percent more proteins and speed up the biomarker discovery process 10-fold, follows platform launches in the fall meant to put them back at the top of the mass-spec food chain.

Industry Briefs: Mar 19, 2009

Premium

MDS, Aushon BioSystems, Thermo Fisher Scientific, Oxford Genome Technology, Sense Proteomic, Institute for Bioanalytics, Axela, Arrayit

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.